Injection-Related Risks & POME
PIP, Abscess/Infection, Oil-Based Technique, and Pulmonary Oil Microembolism
Evidence grade 4 of 5, Strong. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- POME is an FDA Boxed Warning (Aveed); Aveed restricted via REMS
Reference only. Not medical advice.
What can go wrong
Common: post-injection pain, swelling, and bruising; site reactions are more frequent with larger volumes and irritant carriers. Infectious: abscess and cellulitis from poor sterile technique, a real hazard in unsupervised self-injection and amplified with non-sterile underground products. Serious and rare: pulmonary oil microembolism and anaphylaxis, which for testosterone undecanoate carry an FDA Boxed Warning and a REMS mandating 30-minute post-injection observation. Other injection hazards include nerve injury from poor site selection and bloodborne infection from shared or reused needles.
This is something to take to a clinician. The Atlas can tell you what is known about injection-related risks & pome in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Injectable testosterone esters are oil-based, which creates a distinct risk set: post-injection pain (PIP) from irritant carriers, sterile and infectious complications including abscess, and, rarely, pulmonary oil microembolism (POME) when oil enters the circulation. POME and anaphylaxis carry an FDA Boxed Warning for testosterone undecanoate (Aveed), which is restricted to a REMS program requiring 30-minute post-injection observation. This dossier covers technique-related risk and the serious rare events.
An oil injection is a minor procedure with a real, occasionally serious, complication profile.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
Testosterone esters are dissolved in oil so they release slowly from a muscle depot; the oil vehicle and solubilizers (benzyl alcohol, benzyl benzoate) can irritate tissue and cause post-injection pain, especially with larger volumes, faster esters, or higher concentrations. Non-sterile technique can introduce bacteria, producing cellulitis or abscess. POME occurs when oil enters the venous circulation (e.g., inadvertent intravascular delivery) and lodges in pulmonary capillaries, producing an acute reaction; anaphylaxis to vehicle components (e.g., benzyl benzoate) is a separate immune event.
Why testosterone undecanoate carries a Boxed Warning
Testosterone undecanoate injection (Aveed) is given as a large-volume (3 mL) oil depot, and serious POME reactions, urge to cough, dyspnea, throat tightening, chest pain, dizziness, syncope, plus episodes of anaphylaxis, have been reported during or immediately after administration, including after the very first dose. Because of this, FDA placed a Boxed Warning and restricted Aveed to a REMS program: it can only be given in certified healthcare settings with emergency equipment, and the patient must be observed for 30 minutes after each injection. This is the clearest regulatory signal that oil-depot testosterone injection is a genuine procedure, not a casual self-administered shot.
Safety in detail
This intervention involves significant physiological effects and requires evaluation and monitoring by a qualified physician. Self-administration without medical oversight carries documented health risks, including rare but serious pulmonary oil microembolism and anaphylaxis.
- PIP from oil carriers and solubilizers, worse with larger volumes
- Abscess/cellulitis from non-sterile technique
- POME: oil reaching pulmonary capillaries causes acute symptoms
- Anaphylaxis can occur, even after the first dose
- Aveed carries an FDA Boxed Warning and REMS (30-min observation)
- Shared/reused needles risk bloodborne infection
Replacement is not the same as a cycle
Risk is highest with unsupervised, high-frequency self-injection of underground-lab oils, where sterility, concentration, and carrier quality are unknown, abscesses and PIP are common, and there is no clinical observation for rare POME/anaphylaxis. Supervised replacement-dose injection in a clinic mitigates much of this.
What it does to fertility
Injection technique itself does not affect fertility; the underlying testosterone does (see HPG-axis and spermatogenesis entries).
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Sterile technique and correct site/depth
- 30-minute observation for testosterone undecanoate (REMS)
- Emergency readiness for POME/anaphylaxis in certified settings
- Injection-site inspection for infection/abscess
What people get wrong
Often saidInjecting testosterone is just like any other shot
ActuallyOil-based depot injection has a distinct risk set, irritant carriers, abscess risk, and the rare but serious POME/anaphylaxis, which is why testosterone undecanoate requires supervised administration and observation.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
At a glance
- Carrier
- Oil vehicle (e.g., castor, sesame, cottonseed) + benzyl alcohol/benzoate
- PIP
- Post-injection pain from irritant carriers / large volume
- Infection
- Abscess/cellulitis from non-sterile technique
- POME
- Oil microembolism: cough, dyspnea, syncope
- Aveed
- FDA Boxed Warning; REMS; 30-min observation
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Injection-Related Risks & POME. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
FDA Boxed Warning and REMS for Aveed (testosterone undecanoate)2014
Required certified settings and 30-minute observation due to serious POME and anaphylaxis reports, including after first dose
Postmarketing safety analysis of POME after testosterone undecanoate2020
Characterized POME event reports, supporting the observation requirement
Case report: anaphylaxis to benzyl benzoate in depot testosterone undecanoate2012
Implicated a vehicle component as a cause of severe reaction, distinguishing anaphylaxis from POME